ClinicalTrials.gg
TerminatedNCT00587275Updated Jun 18, 2014

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

A Phase 2 interventional study of AST-120 and Celphere CP-305 in Gastroesophageal Reflux Disease (GERD), sponsored by Ocera Therapeutics. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-18.

Sponsored by Ocera Therapeutics (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Why this study was terminated
Terminated for lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 421 studies in Gastroesophageal Reflux with a site in United States — 55 open to participants now, 70 under way, 2 of them phase 3. Gastroesophageal Reflux · United States.

Enrollment
278th of 302
4 · median 60
Started
2007
with 25 others
Phase 2
35 of 421
2 open now
Registered
95th of 421
by date

Among the 421 studies in Gastroesophageal Reflux with a site in United States, this one is the 278th largest by enrollment of the 302 interventional ones that give a count, is one of 26 that started in 2007, is one of 35 in phase 2, and was the 95th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

55 of the 421 studies in Gastroesophageal Reflux with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 421 studies in Gastroesophageal Reflux with a site in United States, or all of them as a file.
02

Study summary

The purpose of this project is to test how safe and how well AST-120, an investigational product, works in treating too much acid in the stomach. Patients will be randomly assigned to one of two groups, AST-120 or a placebo for the first four weeks of the study. The patients will be switched to the other group (AST-120 or placebo)for the following four weeks.

Read the detailed description

This is a double-blind, randomized, placebo-controlled, crossover trial where 20 patients with confirmed persistent GERD symptoms (at least twice weekly) after a standard course of PPI, with abnormal bile reflux levels but normal esophageal acid exposure are randomized to initially receive either AST-120 or placebo for a period of 4 weeks after a two week screening period. After a washout period of one week, patients will cross over to the opposite blinded treatment.

The experimental drug AST-120 is composed of black, odorless spherical carbon particles in 2g sachets (aluminum foil pouches). The placebo consists of microcrystalline cellulose spheres, Celphere CP-305, stained to match the appearance of AST-120, in 2g sachets (aluminum foil pouches). Both AST-120 and placebo are oral (taken by mouth) preparations. Both are tasteless. Take the product, patients will tear open the sachet, drop the contents directly on their tongue and wash it down with 8 ounces of water.

Patients will continue to receive the previously prescribed PPI throughout the duration of the trial. In addition, patients will be allowed up to 6 Gelusil tablets daily as a "rescue medication".

Patients will be expected to participate in approximately 5 in-clinic visits. During these visits, patients will undergo a number of tests including: comprehensive physical, hematology panel, a urine pregnancy test for pre-menopausal females, completion of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) and Short-Form-36 (SF-36)Quality of Life Form and an upper endoscopy will be performed to determine the extent of esophageal inflammation.

Patients will be allowed to continue on their previously prescribed PPI with no changes and may take up to 6 Gelusil tablets per day. The following therapies must be discontinued and should not be taken during the trial: H2receptor antagonists, NSAIDs, Baclofen and Antacids (OTC or prescription).

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)

Keywords

  • Gastroesophageal Reflux Disease
  • GERD
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight 40 to 136 kg (88 to 300 lbs)
  • Recent history of GERD related symptoms (at least twice weekly) confirmed during screening.
  • Recent history of 8 week PPI treatment without significant improvement
  • Abnormal level as assessed by Bilitec
  • Normal esophageal pH value (pH\<4.0 for \<4.2% of the time calculated over a 24 hour period)
  • count (thrombocytes) >100,000/µL
  • Normal and Hct levels
  • Able and willing to comply with all protocol procedures for the planned duration of the study
  • Able and willing to understand, sign and date an document, and authorize access to protected health information.
  • Females must be , surgically incapable of bearing children, or practicing a reliable method of (hormonal contraceptives, intrauterine devices, spermicide and barrier). Partner/spouse sterility may also qualify at the Investigator's discretion. Females of must have a negative urine pregnancy test at baseline.

Exclusion criteria

Exclusion Criteria:

  • Concurrent GI or other pathology which could interfere with the course of the study (e.g., erosive esophagitis, malabsorption, cirrhosis, ascites, bleeding ulcer, diabetes, scleroderma, non-GI myopathy or neuropathy etc.) Note: patients with Barrett's esophagus (short segment defined as \< 3 cm) can be included.
  • Patients with cancer or undergoing chemotherapy for the treatment of cancer
  • Patients with a history of upper GI surgery
  • Patients with GERD complications such as stricture of the esophagus
  • to continued PPI treatment
  • Patients requiring the concomitant use of NSAIDs for the duration of the study
  • Uncontrolled systemic disease
  • Diagnosis of a psychiatric disorder within the past 2 years and not on a stable dose of medications for at least 6 months
  • Other major physical or psychiatric illness in previous 6 months as determined by the treating physician
  • Known or contraindication to any component of the test product (study drug) or diagnostics used
  • Participation in another study within eight (8) weeks prior to randomization
  • Unable to attend all visits required by the protocol
  • Pregnant, breast feeding, or planning to become pregnant during the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    1

    AST-120, 2 gram sachets

    Drug: AST-120

  • Placebo comparator
    2

    Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.

    Drug: Celphere CP-305

Interventions

  • DrugAST-120

    Drug pages: AST 120 · Charcoal

    Oral, sachet, 2 grams daily for 4 weeks

  • DrugCelphere CP-305

    Oral, sachet, 2 grams daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. Reduction in the severity of GERD symptoms in patients receiving AST-120 assessed by comparing the symptom scores on the GSAS.

    Time frame: 8 weeks

  2. Safety endpoint is adverse events (AEs)deemed possibly, probably, or definitely related to treatment with investigational product.

    Time frame: 8 weeks

Secondary outcomes

  1. Reduction in severity of GERD symptoms in patients receiving AST-120 assessed by patient self assessment using a daily diary.

    Time frame: 8 weeks

  2. Percent days without heartburn.

    Time frame: 8 weeks

  3. Percent daytime period without heartburn.

    Time frame: 8 weeks

  4. Percent change in SF-36 score.

    Time frame: 8 weeks

  5. Esophageal bilirubin levels as measured by Bilitec.

    Time frame: 8 weeks

  6. Amount of rescue medication (Gelusil) taken per day.

    Time frame: 8 weeks

  7. Changes in clinical laboratory tests from baseline.

    Time frame: 8 weeks

  8. Prior and concomitant medications.

    Time frame: 8 weeks

  9. Physical examination, vital signs (blood pressure, heart rate, respiration rate and temperature).

    Time frame: 8 weeks

  10. GI tolerability (diarrhea, constipation, etc).

    Time frame: 8 weeks

07

Study locations

1 site
  • Southern Arizona VA Health Care System and University of Arizona Health Sciences Center
    Tucson, Arizona 85723, United States
08

References and documents

Publications

  • Xu XR, Li ZS, Zou DW, Xu GM, Ye P, Sun ZX, Wang Q, Zeng YJ. Role of duodenogastroesophageal reflux in the pathogenesis of esophageal mucosal injury and gastroesophageal reflux symptoms. Can J Gastroenterol. 2006 Feb;20(2):91-4. doi: 10.1155/2006/498142. PubMed 16482234 ↗
  • Fennerty MB. Review article: alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther. 2005 Dec;22 Suppl 3:39-44. doi: 10.1111/j.1365-2036.2005.02711.x. PubMed 16303036 ↗
  • Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next? Aliment Pharmacol Ther. 2005 Jul 15;22(2):79-94. doi: 10.1111/j.1365-2036.2005.02531.x. PubMed 16011666 ↗
  • Fukuda Y, Takazoe M, Sugita A, et al. The treatment with an oral spherical adsorptive carbon (AST-120) improves anal fistula, PDAI and CDAI scores - A randomized double-blind placebo controlled trial. Abstract #765 presented at Digestive Disease Week meeting, Los Angeles, CA May 24, 2006
  • Yamazaki Z, Fujimori T, Yoshimoto T, et al. Effect of Oral Adsorbent on Animal Models of Hepatic Failure 92(2):331-335, 1980
  • Araki Y, Tsujikawa T, Andoh A, Sasaki M, Fujiyama Y, Bamba T. Therapeutic effects of an oral adsorbent on acute dextran sulphate sodium-induced colitis and its recovery phase in rats, especially effects of elimination of bile acids in gut lumen. Dig Liver Dis. 2000 Nov;32(8):691-8. doi: 10.1016/s1590-8658(00)80332-1. PubMed 11142579 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Jan 7, 2008
Start
Oct 2007
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results delay requested
Jul 26, 2013
Last update
Jun 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00587275
Lead sponsor
Ocera Therapeutics
Responsible party
Sponsor
First posted
Jan 7, 2008
Start date
Oct 2007
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Jun 18, 2014

Study contacts

Ronnie Fass, MD
principal investigator · Southern Arizona VA Health Care System

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AST 120 · Charcoal

Start the discussion